Explore

Trendline Trendline
WuXi Biologics Achieves ISO 13485 Certification, Enhancing Drug-Device Product Development

WuXi Biologics Achieves ISO 13485 Certification, Enhancing Drug-Device Product Development

WuXi Biologics Achieves ISO 13485 Certification, Enhancing Drug-Device Product Development
Trendline Trendline
AbbVie Enters Pain Management Market with $715M Deal with Haisco

AbbVie Enters Pain Management Market with $715M Deal with Haisco

AbbVie Enters Pain Management Market with $715M Deal with Haisco
Trendline Trendline
Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial
Trendline Trendline
Replimune Faces Challenges After Second FDA Rejection of Melanoma Drug

Replimune Faces Challenges After Second FDA Rejection of Melanoma Drug

Replimune Faces Challenges After Second FDA Rejection of Melanoma Drug
Trendline Trendline
Avantor Expands U.S. Biomanufacturing with New Testing Facility in St. Louis

Avantor Expands U.S. Biomanufacturing with New Testing Facility in St. Louis

Avantor Expands U.S. Biomanufacturing with New Testing Facility in St. Louis
Trendline Trendline
Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceutical Alliance
Trendline Trendline
Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach

Co-Diagnostics to Present Co-Dx PCR Platform at ESCMID 2026, Aiming to Expand Global Reach
Trendline Trendline
Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer

Regeneron Partners with Telix in $4.3 Billion Radiopharmaceuticals Deal Targeting Cancer
Trendline Trendline
FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion
Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul
Trendline Trendline
Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments

Avalyn Pharma Files for IPO to Fund Respiratory Disease Treatments
Trendline Trendline
FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time